AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 159 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,514,177 | +27.2% | 182,391 | +45.5% | 0.00% | 0.0% |
| Q2 2023 | $3,549,317 | -37.4% | 125,329 | -49.2% | 0.00% | 0.0% |
| Q1 2023 | $5,670,604 | -5.7% | 246,870 | +15.3% | 0.00% | -25.0% |
| Q4 2022 | $6,013,585 | -6.4% | 214,159 | -5.7% | 0.00% | -20.0% |
| Q3 2022 | $6,423,000 | +63.8% | 227,120 | +28.4% | 0.01% | +150.0% |
| Q2 2022 | $3,922,000 | +46.5% | 176,884 | +92.3% | 0.00% | -33.3% |
| Q1 2022 | $2,677,000 | -46.8% | 91,960 | -39.9% | 0.00% | 0.0% |
| Q4 2021 | $5,031,000 | +98.5% | 153,054 | +178.6% | 0.00% | +200.0% |
| Q3 2021 | $2,535,000 | -51.0% | 54,941 | -41.4% | 0.00% | -66.7% |
| Q2 2021 | $5,170,000 | -7.4% | 93,807 | -13.2% | 0.00% | -25.0% |
| Q1 2021 | $5,583,000 | +293.7% | 108,126 | +230.4% | 0.00% | +300.0% |
| Q4 2020 | $1,418,000 | -81.9% | 32,722 | -85.4% | 0.00% | -80.0% |
| Q3 2020 | $7,853,000 | +29.8% | 224,388 | +98.3% | 0.01% | 0.0% |
| Q2 2020 | $6,051,000 | +105.6% | 113,155 | +36.4% | 0.01% | +150.0% |
| Q1 2020 | $2,943,000 | -38.0% | 82,948 | -16.6% | 0.00% | -33.3% |
| Q4 2019 | $4,745,000 | +8.7% | 99,406 | -26.2% | 0.00% | 0.0% |
| Q3 2019 | $4,366,000 | -18.6% | 134,772 | +25.3% | 0.00% | -25.0% |
| Q2 2019 | $5,363,000 | +31.3% | 107,520 | +77.5% | 0.00% | 0.0% |
| Q1 2019 | $4,083,000 | -32.3% | 60,558 | -53.7% | 0.00% | -42.9% |
| Q4 2018 | $6,031,000 | +26.6% | 130,787 | +111.7% | 0.01% | +75.0% |
| Q3 2018 | $4,765,000 | -1.4% | 61,783 | +7.7% | 0.00% | -20.0% |
| Q2 2018 | $4,834,000 | +47.4% | 57,389 | +43.1% | 0.01% | +150.0% |
| Q1 2018 | $3,279,000 | +180.0% | 40,098 | +95.7% | 0.00% | – |
| Q4 2017 | $1,171,000 | +24.4% | 20,493 | +45.4% | 0.00% | – |
| Q3 2017 | $941,000 | -10.2% | 14,097 | -30.8% | 0.00% | – |
| Q2 2017 | $1,048,000 | -50.7% | 20,378 | -44.1% | 0.00% | -100.0% |
| Q1 2017 | $2,127,000 | +521.9% | 36,434 | +344.3% | 0.00% | – |
| Q4 2016 | $342,000 | -70.6% | 8,200 | -62.8% | 0.00% | -100.0% |
| Q3 2016 | $1,164,000 | +53.8% | 22,043 | +21.9% | 0.00% | 0.0% |
| Q2 2016 | $757,000 | -59.9% | 18,078 | -61.1% | 0.00% | -50.0% |
| Q1 2016 | $1,888,000 | -10.8% | 46,519 | +42.8% | 0.00% | 0.0% |
| Q4 2015 | $2,117,000 | -36.6% | 32,585 | -31.1% | 0.00% | -33.3% |
| Q3 2015 | $3,340,000 | -51.4% | 47,315 | -23.5% | 0.00% | -50.0% |
| Q2 2015 | $6,871,000 | +174.9% | 61,830 | +133.3% | 0.01% | +200.0% |
| Q1 2015 | $2,499,000 | +94.5% | 26,503 | +131.1% | 0.00% | +100.0% |
| Q4 2014 | $1,285,000 | +780.1% | 11,469 | +381.9% | 0.00% | – |
| Q3 2014 | $146,000 | +1023.1% | 2,380 | +753.0% | 0.00% | – |
| Q2 2014 | $13,000 | -90.5% | 279 | -92.0% | 0.00% | – |
| Q1 2014 | $137,000 | -23.9% | 3,504 | -53.3% | 0.00% | – |
| Q4 2013 | $180,000 | +542.9% | 7,509 | +650.9% | 0.00% | – |
| Q3 2013 | $28,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |